Meeting
2023 ASCO Annual Meeting
Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors.
Authors
Chia-Chi Lin
National Taiwan University Hospital, Taipei, Taiwan
Chia-Chi Lin , Nai-Jung Chiang , Jih-hsiang Lee , Ming-Huang Chen , Yee Chao , Wu-Chou Su , Li-Yuan Bai , Shang-Yin Wu , Chih-Hung Hsu , Yan-Shen Shan , Chung-Pin Li , Shang-Hung Chen , Wei-Pang Chung , Li-Tzong Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Other Developmental Therapeutics
Clinical Trial Registration Number
NCT01800630 ,NCT03531320
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3148)
DOI
10.1200/JCO.2023.41.16_suppl.3148
Abstract #
3148
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
First Author: Ryan Leibrandt
Poster
2019 ASCO Annual Meeting
A phase I study of pazopanib with weekly paclitaxel and carboplatin in advanced solid tumors.
First Author: Nancy Chan
Poster
2019 ASCO Annual Meeting
Phase I study of the Aurora A kinase (AurA) inhibitor TAS-119 with paclitaxel (P) in advanced solid tumors.
First Author: Dana Backlund Cardin